Aktienanalyse zu Alumis Inc. (ALMS)ALMSAlumis Inc.

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alumis Inc is currently not a strong buy. The stock is priced at $7.16, with an RSI of 44.8 indicating it is nearing oversold territory, but the recent 20-day change is down 22.00%. While there are positive developments in the pipeline, such as potential FDA approval for psoriasis treatment, the significant risks from the failed lupus trial and a negative net income of -142221000 USD in Q2 2026 are concerning. The insider buying activity has increased by 586.17%, which is a positive sign, but the overall market sentiment remains cautious due to the recent price declines and analyst downgrades.